Kura Oncology (NASDAQ:KURA) Trading Up 5.5%

Kura Oncology Inc (NASDAQ:KURA) shares were up 5.5% during mid-day trading on Wednesday . The company traded as high as $17.70 and last traded at $17.53. Approximately 184,100 shares changed hands during mid-day trading, a decline of 8% from the average daily volume of 199,997 shares. The stock had previously closed at $16.61.

A number of research firms recently commented on KURA. BidaskClub cut shares of Kura Oncology from a “hold” rating to a “sell” rating in a research note on Tuesday, April 16th. ValuEngine cut shares of Kura Oncology from a “buy” rating to a “hold” rating in a research note on Wednesday, February 13th. Oppenheimer reiterated a “buy” rating on shares of Kura Oncology in a research note on Tuesday, March 19th. HC Wainwright set a $31.00 target price on shares of Kura Oncology and gave the stock a “buy” rating in a research note on Wednesday, May 8th. Finally, Zacks Investment Research upgraded shares of Kura Oncology from a “hold” rating to a “buy” rating and set a $19.00 target price for the company in a research note on Wednesday, May 29th. One research analyst has rated the stock with a hold rating and eight have issued a buy rating to the company. Kura Oncology has an average rating of “Buy” and an average target price of $27.83.

The company has a market capitalization of $641.21 million, a P/E ratio of -10.19 and a beta of 2.44. The company has a debt-to-equity ratio of 0.05, a quick ratio of 13.80 and a current ratio of 13.80.

Kura Oncology (NASDAQ:KURA) last announced its quarterly earnings data on Tuesday, May 7th. The company reported ($0.37) EPS for the quarter, beating the consensus estimate of ($0.45) by $0.08. On average, research analysts expect that Kura Oncology Inc will post -1.77 EPS for the current year.

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Bank of New York Mellon Corp increased its holdings in shares of Kura Oncology by 9.7% during the 3rd quarter. Bank of New York Mellon Corp now owns 112,255 shares of the company’s stock valued at $1,965,000 after purchasing an additional 9,884 shares in the last quarter. Vanguard Group Inc. increased its holdings in shares of Kura Oncology by 2.1% during the 3rd quarter. Vanguard Group Inc. now owns 1,455,818 shares of the company’s stock valued at $25,477,000 after purchasing an additional 29,785 shares in the last quarter. Rhumbline Advisers increased its holdings in shares of Kura Oncology by 59.1% during the 4th quarter. Rhumbline Advisers now owns 37,118 shares of the company’s stock valued at $521,000 after purchasing an additional 13,781 shares in the last quarter. Alps Advisors Inc. increased its holdings in shares of Kura Oncology by 30.8% during the 4th quarter. Alps Advisors Inc. now owns 87,899 shares of the company’s stock valued at $1,234,000 after purchasing an additional 20,698 shares in the last quarter. Finally, Victory Capital Management Inc. increased its holdings in shares of Kura Oncology by 10.1% during the 4th quarter. Victory Capital Management Inc. now owns 1,692,220 shares of the company’s stock valued at $23,759,000 after purchasing an additional 155,910 shares in the last quarter. Institutional investors and hedge funds own 83.93% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Kura Oncology (NASDAQ:KURA) Trading Up 5.5%” was originally posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this article on another site, it was copied illegally and republished in violation of U.S. & international copyright legislation. The original version of this article can be viewed at https://www.dispatchtribunal.com/2019/06/12/kura-oncology-nasdaqkura-trading-up-5-5.html.

Kura Oncology Company Profile (NASDAQ:KURA)

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer. The company's lead product candidate is Tipifarnib, an oral farnesyl transferase inhibitor that is in Phase II clinical trials for the treatment of solid tumors, peripheral T-cell lymphomas, myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia.

Featured Story: Why are percentage decliners important?

Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.